首页> 外文期刊>Journal of hepato-biliary-pancreatic sciences >Effects of modified splenocaval shunt plus devascularization on esophagogastric variceal bleeding: a comparative study of this treatment and devascularization only in cirrhotic portal hypertension.
【24h】

Effects of modified splenocaval shunt plus devascularization on esophagogastric variceal bleeding: a comparative study of this treatment and devascularization only in cirrhotic portal hypertension.

机译:改进的脾脏分流术对食管毒性静脉曲张出血的影响:仅在肝硬化门骨高血压中对该治疗和脱垂性的对比研究。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Pericardial devascularization (PCDV) and portosystemic shunt were reported to have favorable results for the management of portal hypertension in cirrhotic patients in China and the West, respectively. This study was undertaken to investigate the effects of a modified proximal splenocaval shunt plus PCDV on variceal bleeding in patients with portal hypertension. METHODS: From January 1997 to December 2007, 168 patients with portal hypertension of cirrhotic origin received an operation for gastroesophageal variceal bleeding. Of these, 90 patients received a splenocaval shunt plus a PCDV procedure (Combined Group) and the other 78 patients received a PCDV procedure only (PCDV Group). The procedure-related morbidity and mortality, rebleeding, encephalopathy, and survival rates were analyzed. RESULTS: Postoperative mortality was 3.3% in the combined group and 5.1% in the PCDV group (P > 0.05). Overall morbidity was 13.3% in the combined group and 15.4% in the PCDV group (P > 0.05). The rate for rebleeding, including variceal bleeding and gastropathy, was 5.1% in the combined group, which was significantly lower than that in the PCDV group, at 16.7% (P < 0.05). The incidence of encephalopathy was 6.63% in the combined group and 6.67% in the PCDV group (P > 0.05). The 1-, 3-, 5- and 10-year survival rates were 97.4, 91.7, 80.0, and 60.0% in the combined group and 96.7, 83.3, 73.3, and 53.3% in the PCDV group (P > 0.05). CONCLUSIONS: The modified splenocaval shunt plus PCDV is a safe and effective procedure for the long-term control of variceal bleeding; the procedure may not only maintain the portal flow to the liver, but may also protect the liver function in cirrhotic patients. The better clinical outcome means that the procedure may be one of the best choices for treating portal hypertension of cirrhotic origin.
机译:背景:据报道,心包偏移(PCDV)和PortoSystemic分流器分别在中国和西部的肝硬化患者中的门尔高血压管理有利。本研究旨在调查改良的近端脾脏分流器PCDV在门静脉高压患者中对静脉曲张出血的影响。方法:1997年1月至2007年12月,168例肝硬化的肝硬化血管高血压患者接受了胃食管瓦氏血清出血的操作。其中,90名患者接受了脾脏载流子分流加上PCDV程序(联合组),另一个78名患者仅接受PCDV程序(PCDV组)。分析了与程序相关的发病率和死亡率,再释放,脑病和生存率。结果:合并组的术后死亡率为3.3%,PCDV组中的5.1%(P> 0.05)。合并组的总体发病率为13.3%,PCDV组15.4%(P> 0.05)。在组合组中,加工率包括静脉曲张出血和胃病,其速率明显低于PCDV组,16.7%(P <0.05)。合并组的脑病发病率为6.63%,PCDV组中的6.67%(P> 0.05)。组合组的1-,3-,5-和10年生存率为97.4,91.7,80.0和60.0%,PCDV组中的96.7,83.3,73.3和53.3%(P> 0.05)。结论:改进的脾脏分流器加上PCDV是一种安全有效的变形流血控制的程序;该程序不仅可以将门静脉流入肝脏,而且还可能保护肝硬化患者的肝功能。更好的临床结果意味着该程序可以是治疗肝硬化起源的门静脉血高血压的最佳选择之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号